WGS — GeneDx Holdings Balance Sheet
0.000.00%
- $1.67bn
- $1.57bn
- $427.54m
Annual balance sheet for GeneDx Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 401 | 124 | 130 | 141 | 171 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 26.6 | 43.3 | 32.8 | 37.6 | 74.4 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 484 | 213 | 182 | 198 | 268 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 62.7 | 84.3 | 59.4 | 58.5 | 69.1 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 554 | 491 | 419 | 419 | 524 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 101 | 144 | 58.8 | 54.8 | 109 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 166 | 237 | 191 | 174 | 216 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 388 | 254 | 228 | 245 | 308 |
| Total Liabilities & Shareholders' Equity | 554 | 491 | 419 | 419 | 524 |
| Total Common Shares Outstanding |